...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

Koo -

clinical trials.gov #
NCT03901469

i errored earlier - this is trial 5 of the 19 listed under Zen3694

Chicagoest

Share
New Message
Please login to post a reply